Diabetes Market Forecast to 2015 (TA224)

&nsbp;
 
 

  • Comprehensive Diabetes Market Forecast

    Gain instant access to the most up-to-date information on the diabetes market. Scour in-depth profiles of brands and diabetes drug makers to target and seize market share, optimize return on investment, prove the value of your assets, and set proactive brand strategies.

    In addition to market forecasts, you'll find primary data from physicians worldwide as well as industry leaders in R&D and marketing. Their input provides knowledgeable, fresh insights on emerging treatments and unmet needs in the diabetes space.

    Get accurate, honest market outlooks. Save money and valuable time with sales projections, patent information and clinical data — all in context, so you can compare brands, classes and companies.

    Answer critical questions about your diabetes portfolio:

    • Are you entering the diabetes market — or expanding your current portfolio?
    • How does your developing drug compare to brands on the market? Does your drug stand a chance?
    • Are you working on another DPP-4 inhibitor or GLP-1 analog — and ignoring a market push toward novel therapies?
    • Have you been hit by the FDA's cardiovascular guidelines? Are you adequately prepared for regulatory review?
    • Are you trying to out-license a diabetes product?
    • How will your early-stage diabetes compound fare in tomorrow's market? Is there room for your drug, too?
    Back to Top
  • Companies Included in Diabetes Market Forecast Research

    Profiled Diabetes Portfolios

    • Amylin
    • Bristol-Myers Squibb
    • Boehringer Ingelheim
    • Eli Lilly
    • GlaxoSmithKline
    • Merck
    • Novo Nordisk
    • Roche
    • Sanofi-Aventis
    • Takeda

     

    All Companies Included in Report

    • Alkermes
    • Amylin
    • AstraZeneca
    • Biocon
    • Biodel
    • Boehringer Ingelheim
    • Bristol-Myers Squibb
    • Eisai
    • Eli Lilly
    • Forest Labs
    • Generex
    • Genzyme
    • Gideon Richter
    • GlaxoSmithKline
    • Human Genome Sciences
    • Ipsen
    • MacroGenics
    • Mannkind
    • Merck
    • Novartis
    • Novo Nordisk
    • Osiris
    • Pfizer
    • Phenomix
    • Quark
    • Roche
    • Sanofi-Aventis
    • Takeda
    • Tolerx
    • Transition Therapeutics
    • Vivus
    Back to Top
  • Diabetes Market Forecast Metrics

    Background

    • Current status of drug (e.g., in development, awaiting approval, on market)
    • Clinical results and what they mean for the drug's future
    • Drug's current and projected competitive strength
    • Current and projected sales position within its class
    • Assessment of current and future competition

     

    Market Growth

    • Analysis combines current sales, market landscape and/or clinical trial info with projections and predicted market events
    • Sales projection charts through 2015
    • Materiality charts (drug's percentage of company revenue) for 2009 (or first year on market) and 2015

     

    Patents and Generics

    • Market exclusivity charts
    • Patent information for approved drugs

     

    Clinical Trial Data

    • Details most important current trials
    • Trial title, identification number, and description
    • Start and end dates

     

    Diabetes Drug Manufacturer Profiles

    • Diabetes ranking
    • Overall industry ranking
    • Strengths analysis
    • Growth areas analysis
    • Market opportunities analysis
    • Key products breakdown

     

    Perspectives on the Industry (from physicians, marketers, and developers)

    • Unmet needs
    • Emerging treatments
    • Cardiovascular guidelines
    Back to Top
  • Back to Top

The Benefit:

Track long-term forecasts and in-depth brand profiles of 45 drugs for a comprehensive look at the future of the diabetes market.